A2 Biotherapeutics, Inc.

A2 Bio will present a poster today titled, “Cytokine response and heme cell depletion and recovery after treatment with Tmod logic?gated CAR Ts in patients with solid tumors,” at the SITC Spring Scientific, Cellular Therapy for Solid Tumors. Please join A2 Bio and J. Randolph Hecht, MD, from the UCLA Jonsson Comprehensive Cancer Center, Thursday, March 13, 2025, 5-6:30 pm, at Poster #52 in the Aragon I Room, Rancho Bernardo Inn, San Diego, California. After the event, the poster will be available on the A2 Bio's publications page: https://lnkd.in/g8CiubqZ For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #SITCSpringScientific #A2Bio #Tmod #CellTherapy #CART

March is national Kidney Cancer Awareness month. A2 Bio is focused on developing cell therapies that target solid tumors such as kidney cancer. Our BASECAMP-1 (NCTO4981119) pre-screening study is currently enrolling patients with renal cell carcinoma and other solid tumors. BASECAMP-1 is a non-interventional study that leverages clinical diagnostics to efficiently identify patients eligible for our interventional trials. For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #KidneyCancerAwarenessMonth #A2Bio #Tmod #CellTherapy

March is Colorectal Cancer Awareness Month. At A2 Bio, we're committed to advancing innovative oncology treatments for patients with colorectal cancer, leveraging our logic-gated Tmod? CAR T-cell therapy. A2 Bio has two clinical studies, EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), that are actively enrolling patients with colorectal cancer, as well as other solid tumors. To read more about the EVEREST-1 and EVEREST-2 studies, please visit: https://lnkd.in/ge7KqZ8T #ColorectalCancerAwarenessMonth #BlueForCRC #A2Bio #CellTherapy

Watch this short video by Dr. Kristen Spencer, DO, Associate Professor, Department of Medicine at NYU Grossman School of Medicine and Director, Phase 1 Developmental Therapeutics Program, NYU Langone Perlmutter Cancer Center. Dr. Spencer discusses the rationale for the phase 1/2 EVEREST-2 trial (NCT06051695) to evaluate a novel CAR T-cell product in pancreatic cancer. To view the OncLive TV video, please visit: https://lnkd.in/dv4d5i-P For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #OncLiveTV #A2Bio #Tmod #CellTherapy #CART #NYU

This week, we gathered to celebrate A2 Bio's 7th anniversary and reflect on how far we've come as a cell therapy company. The team enjoyed delicious food and cake to celebrate this achievement. Many thanks to our investors, Board of Directors, patients and their families, investigators and clinical staff in addition to our dedicated employees for helping us achieve this milestone. We are excited to keep the momentum going into 2025 and beyond. #A2Bio #CellTherapy #Tmod

William Go MD,PhD, Chief Medical Officer for A2 Bio, will be attending the IASLC 2025 Targeted Therapies of Lung Cancer Meeting held February 19-22 in Huntington Beach, CA. Dr. Go will meet with investigators to share updates on our phase 1 studies, EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), which are actively enrolling patients with recurrent unresectable, locally advanced, or metastatic non-small cell lung cancer. For more information on A2 Bio clinical studies, please visit: https://lnkd.in/ge7KqZ8T #TTLC25 #A2Bio #Tmod #CellTherapy #CART

A2 Bio will present a poster at the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Tandem Meetings on February 13, 2025 in Honolulu, Hawaii. The poster, titled "Recommendations for Defining Chimeric Antigen Receptor T cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Stage CAR T Therapy Studies", is a collaboration of A2 Bio with an expert panel of academic cell therapists to recommend DLT definitions for early-phase cell therapy studies. Please join A2 Bio, along with Sarah Nikiforow, MD, PhD, Technical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, at Poster ID 611 in Exhibit Hall 3 (HCC) on Thursday, 13 February 2025 at 6:45 pm HST. For more information on A2 Bio's publications, please visit: https://lnkd.in/g8CiubqZ For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #Tandem25 #A2Bio #Tmod #CellTherapy #CART

A2 Bio is proud to present two posters at the 2025 ASCO Gastrointestinal Cancers Symposium on January 24, 2025 from 11:30 am to 1:30 pm PT. Abstract 766 will showcase the utility of BASECAMP-1 (NCT04981119), an ongoing prescreening study. The poster, "Correlation of Mesothelin (MSLN) Expression Measured by RNA Sequencing (RNAseq) and Immunohistochemistry (IHC) in MSLN?Expressing Tumors," will be presented by J. Randolph Hecht, MD, from the UCLA Jonsson Comprehensive Cancer Center. Abstract TP788 will provide a trial in progress update on EVEREST-2 (NCT06051695) a phase 1/2 study of A2B694, a logic?gated Tmod? chimeric antigen receptor T?cell (CAR T) therapy, in patients with pancreatic cancer or other MSLN?expressing solid tumors that have human leukocyte antigen (HLA)–A*02 loss of heterozygosity. This poster will be presented by Kristen Spencer, DO MPH from NYU Langone Health, Perlmutter Cancer Center. For more information on A2 Bio's publications, please visit: https://lnkd.in/g8CiubqZ For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #ASCOGI #A2Bio #Tmod #CellTherapy

We are proud to be recognized by Nasdaq for our $80 Million in Series C Financing. We are thankful for the support of our investors and their confidence in our company. For more information on A2 Bio's press release, please visit: https://lnkd.in/gj5XFe7c For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #A2Bio #Tmod #CellTherapy #Nasdaq

A2 Bio is proud to announce the closing of its $80 Million Series C financing. At A2 Bio, our vision is to create the future of precision cell therapy for people living with cancer and other devastating diseases. This Series C financing will fund the company’s clinical development programs, including EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), and advancement of our pipeline of CAR-T cell therapies based on its proprietary Tmod? platform. For more information, please read the press release at: https://lnkd.in/gj5XFe7c For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #A2Bio #Tmod #CAR-TCellTherapy